Malignant Hypertension in Association with Low Estrogen Dose Oral Contraceptives: Case Report and Review of Literature

Abstract

Malignant hypertension (MH) has been described in association with high-dose (50 - 100 mcg) estrogen oral contraceptive pills (OCPs). Although the rise in blood pressure (BP) is usually mild, some women will have a more significant increase in BP, and hypertensive emergencies may very rarely occur. We present a 21-year-old Caucasian female with a past medical history of fibromyalgia and family history of hypertension (both grandparents) who was admitted with a three-day history of headache and blurring of vision in her left eye with a BP of 210/150. Her medications, which were continued on admission, included tramadol, 100 mg twice daily (bid), and low-dose estrogen OCP. During the hospital course, she received different antihypertensive medications and her hypertension was controlled. A diagnosis of MH due to OCP was made. All antihypertensive medications were stopped, except metoprolol, and the patient was discharged home on metoprolol with a BP of 107/55 mmHg. On follow-up in the medical clinic three months later, her visual disturbances had completely resolved and her BP was 98/56 mmHg. One-third of patients aged 15 - 44 years old who develop MH are likely to be on high-dose estrogen OCP. As far as we know, our case is the third documented case of MH occurring in patients on low-dose estrogen OCP. Chronic use of oral contraceptives will slightly increase the systemic BP in most women. It is advisable to avoid OCP in high-risk patients and do regular BP checks on patients on OCP. In patients presenting with hypertension or MH while on OCP, the OCP should be discontinued.

Mortalidade por doença isquêmica do coração: fatores de riscos e prevenção existentes nas capitais do Brasil no período de 2011 a 2021

“…Quando falamos da terapia com estrogênio e o desenvolvimento da HAS, os estudos atuais são contestáveis, sendo majoritariamente relacionado à reposição hormonal de estrogênio por via oral (com ou sem progestágeno) a um aumento do risco de hipertensão em mulheres no pós-menopausa, aumentando os processos patogênicos da hipertensão, tais como a síntese de PCR (marcador importante da inflamação), angiotensina II (contraindo as arteríolas e aumentando a pressão arterial) e reduzindo o IGF-1, imitando, portanto, a manutenção da função tecidual (MIR D, et al, 2018;SWICA Y, et al, 2018). A proteína C reativa aciona a cascata do complemento, o que estimula citocinas pró-inflamatórias e induz a expressão do fator tecidual.…”

Resistant Hypertension in People With CKD: A Review

“…Estrogencontaining oral contraceptive pills (including low-dose estrogen) have been associated with reversible malignant hypertension and should be avoided in favor of progesterone-based oral contraceptive pills in high-risk patients with RH. 50 Obstructive Sleep Apnea Obstructive sleep apnea (OSA) is strongly associated with RH and should be screened for as part of RH evaluation. 51 Bedside screening tools can help determine when to refer for polysomnography.…”

Efeito do estrogênio no risco cardiovascular: uma revisão integrativa

“…A Terapia de Reposição Hormonal é o tratamento mais eficaz para o alívio dos sintomas vasomotores, como ondas de calor e sudorese noturna nas mulheres no climatério e na menopausa (MEHTA J, et al, 2021). E para milhões de mulheres, as pílulas anticoncepcionais orais são uma maneira eficaz de prevenir uma gravidez indesejada, regular período menstrual e tratamento de problemas devido a mudanças hormonais, como acne (MIR D, et al, 2018).…”

“…Alguns estudos sugerem que os efeitos do estrogênio na pressão arterial podem ser geneticamente mediados (SWICA Y, et al, 2018). Sendo assim, é aconselhável evitar o uso da terapia oral em pacientes de alto risco e fazer verificações regulares da pressão arterial e acompanhamento médico (MIR D, et al, 2018).…”